TR200103188T2 - Sıvı ve katı lipit karışımları temelli lipid parçacıklar. - Google Patents

Sıvı ve katı lipit karışımları temelli lipid parçacıklar.

Info

Publication number
TR200103188T2
TR200103188T2 TR2001/03188T TR200103188T TR200103188T2 TR 200103188 T2 TR200103188 T2 TR 200103188T2 TR 2001/03188 T TR2001/03188 T TR 2001/03188T TR 200103188 T TR200103188 T TR 200103188T TR 200103188 T2 TR200103188 T2 TR 200103188T2
Authority
TR
Turkey
Prior art keywords
lipid
solid
liquid
particles
particle dispersions
Prior art date
Application number
TR2001/03188T
Other languages
English (en)
Inventor
Helmut Müller Rainer
Jenning Volkhard
Mader Karsten
Lippacher Andreas
Original Assignee
Pharmasol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999138371 external-priority patent/DE19938371A1/de
Priority claimed from DE19945203A external-priority patent/DE19945203A1/de
Application filed by Pharmasol Gmbh filed Critical Pharmasol Gmbh
Publication of TR200103188T2 publication Critical patent/TR200103188T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0241—Containing particulates characterized by their shape and/or structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Colloid Chemistry (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Bulus, kati ve sivi lipidlerden yapilmis karisik bir matriksin ilaçsiz ya da ilaç yüklü lipid parçaciklari ile ve % 30'dan % 95'e kadar degisen bir lipid içerigine ya da % 30'dan % 95'e kadar degisen bir kati madde (lipid ve dengeleyici) içerigine sahip olan kati-sivi parçaciklarin çok yogun lipid parçacigi dispersiyonlarinin bir üretim yöntemiyle ilgilidir ki, biamfifilik kremlerin aksine tamamlayici parçaciklardir ve/veya da çok yogun parçacik dispersiyonlarinin dis fazla seyreltilmeleri üzerine serbest akan parçacik dispersiyonlari meydana gelir.
TR2001/03188T 1999-05-07 2000-05-08 Sıvı ve katı lipit karışımları temelli lipid parçacıklar. TR200103188T2 (tr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE19921034 1999-05-07
DE1999138371 DE19938371A1 (de) 1999-08-09 1999-08-09 Zusammensetzung, Herstellung und Verwendung einer Suspension verfestigter, amorpher Öltröpfchen
DE19945203A DE19945203A1 (de) 1999-05-07 1999-09-21 Fest-flüssig (halbfeste) Lipidpartikel (Nano-Compartiment-Carrier-NCC) und Verfahren zur Herstellung hochkonzentrierter Lipidpartikel
DE10016357 2000-03-31

Publications (1)

Publication Number Publication Date
TR200103188T2 true TR200103188T2 (tr) 2002-04-22

Family

ID=27437798

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03188T TR200103188T2 (tr) 1999-05-07 2000-05-08 Sıvı ve katı lipit karışımları temelli lipid parçacıklar.

Country Status (8)

Country Link
EP (1) EP1176949B1 (tr)
JP (1) JP2002544155A (tr)
AU (1) AU4917900A (tr)
BR (1) BR0010354A (tr)
CA (1) CA2369594A1 (tr)
MX (1) MXPA01011343A (tr)
TR (1) TR200103188T2 (tr)
WO (1) WO2000067728A2 (tr)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9908565A (pt) 1998-03-12 2000-12-12 Procter & Gamble Artigo absorvente e processo para reduzir a atividade enzimática de uma enzima fecal em uma parte da pele de um usuário de um artigo absorvente
CN1372452A (zh) * 1999-07-13 2002-10-02 法马索尔股份有限公司 防护有害紫外辐射和增强天然皮肤阻挡层的紫外辐射反射剂或吸收剂
AU2093101A (en) * 1999-12-17 2001-06-25 Procter & Gamble Company, The Compositions for efficient release of active ingredients
CA2408541C (en) * 2000-05-12 2009-07-28 Meracol Corporation Limited Treating eczema and/or psoriasis
US20030153620A1 (en) 2000-05-12 2003-08-14 Meakin Timothy David Treating eczema and/or psoriasis
EP1282412B1 (en) 2000-05-12 2008-01-16 Meracol Corporation Limited Treating irritable bowel syndrome or disease
NZ504526A (en) * 2000-05-12 2003-05-30 Meracol Corp Ltd Treating herpes simplex symptoms using a mixture of cetyl myristate and cetyl palmitate
DE10065217A1 (de) * 2000-12-27 2002-07-18 Pharmasol Gmbh Transfektionskomplexe (TransoPlex) mit reduzierter Toxizität, hoher physikalischer Stabilität und hoher Transfektionseffizienz sowie Verfahren zu ihrer Herstellung
DE10228680A1 (de) * 2002-06-27 2004-01-22 Holden Development Limited, Tortola Grundlage für transdermale Formulierungen (PTF)
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
FR2852843B1 (fr) 2003-03-24 2008-05-23 Karim Ioualalen Systeme galenique permettant le masquage du gout
US20040191207A1 (en) * 2003-03-31 2004-09-30 Lipari John M. Alpha-hydroxy acid ester drug delivery compositions and methods of use
AU2003239845A1 (en) * 2003-05-07 2004-11-26 Ifac Gmbh And Co.Kg Compositions for the targetted release of fragrances and aromas
DE10357640A1 (de) 2003-08-27 2005-03-24 Beiersdorf Ag Kosmetische kugelförmige Zubereitungen zur topischen Anwendung
WO2005020940A1 (de) 2003-08-27 2005-03-10 Beiersdorf Ag Kapsel deren kapselhülle bei topischer anwendung nicht mehr gesondert warhnembar ist
WO2005020949A1 (de) 2003-08-27 2005-03-10 Beiersdorf Ag Kosmetische kugelförmige zubereitungen zur topischen anwendung
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
EP2049081B1 (en) 2006-08-09 2012-11-14 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
WO2008058755A1 (en) 2006-11-17 2008-05-22 Abbott Gmbh & Co. Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
HRP20130259T1 (hr) 2007-04-23 2013-04-30 Intarcia Therapeutics, Inc. Suspenzijske formulacije inzulinotropnih peptida i njihove uporabe
DE102007055341A1 (de) 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
EP2229936B1 (en) * 2009-03-09 2015-05-06 PharmaSol GmbH Nanonized testosterone formulations for improved bioavailability
SMT201700583T1 (it) 2009-09-28 2018-01-11 Intarcia Therapeutics Inc Instaurazione e/o terminazione rapida di erogazione di farmaci in modo sostanzialmente stazionario
ES2384060B1 (es) 2010-03-24 2013-09-23 Lipotec S.A. Cápsulas de nanopartículas lipídicas.
EP2441441A1 (en) * 2010-10-14 2012-04-18 Deva Holding Anonim Sirketi A sieving method for cetyl myristate and/or cetyl palmitate
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
GB201021937D0 (en) * 2010-12-24 2011-02-02 Reckitt & Colman Overseas Skin sanitizer compositions comprising alcohol based emulsion
EA024947B1 (ru) * 2010-12-28 2016-11-30 Юнилевер Нв Способ получения эмульсии
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2012127037A2 (en) * 2011-03-24 2012-09-27 Leo Pharma A/S A composition comprising lipid nanoparticles and a corticosteroid or vitamin d derivative
CN103957888B (zh) * 2011-09-29 2017-11-21 PLx 制药公司 用于将药物沿胃肠道靶向释放的pH依赖性载体、其组合物及其制备和应用
CN102688152A (zh) * 2012-06-05 2012-09-26 东南大学 复合防晒剂纳米结构脂质载体及其制备方法
ES2763352T3 (es) * 2013-01-14 2020-05-28 Infirst Healthcare Ltd Composiciones de solución sólida y uso en inflamación crónica
AU2014204739B2 (en) * 2013-01-14 2016-08-11 Infirst Healthcare Limited Compositions and methods for treating severe pain
HK1218621A1 (zh) * 2013-02-04 2017-03-03 Infirst Healthcare Limited 用於治疗慢性炎症和炎性疾病的组合物及方法
DE102013224627A1 (de) 2013-11-29 2015-06-03 Andreas Lauterbach Pharmazeutische Formulierung mit Lipidmikropartikeln und Herstellungsverfahren
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2017054071A1 (en) * 2015-01-21 2017-04-06 Willinsky Michael Composition and methods to improve stability, dosing, pharmacodynamics and product shelf life of endocannabinoids, phytocannabinoids and synthetic cannabinoids delivered by nasal inhaler
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
EP3228359A1 (en) * 2016-04-06 2017-10-11 Infinitec Activos, S.L. Chlorella compositions and use therof for reducing dark circles under the eyes
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
IL300825A (en) 2017-03-15 2023-04-01 Cerecin Inc Pharmaceutical preparations with a high drug load of medium-length triglyceride chains and methods related thereto
US20210186915A1 (en) * 2018-03-15 2021-06-24 Cerecin Inc. Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto
KR102037354B1 (ko) 2018-12-07 2019-10-28 (주) 바이노텍 생리활성물질 봉입을 위한 나노지질전달체 및 이의 제조방법
EP4054348B1 (en) * 2019-12-10 2026-01-28 Lonza Sales AG Particles containing a lipid matrix core and active ingredient
AU2021244695A1 (en) 2020-03-26 2022-11-10 Plx Opco Inc. Pharmaceutical carriers capable of pH dependent reconstitution and methods for making and using same
DE102023103292A1 (de) * 2023-02-10 2024-08-14 Cineolux Gmbh Dispersion und Zubereitung zur topischen Anwendung
CN116406663A (zh) * 2023-04-11 2023-07-11 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种含草蒿脑的果蝇驱避剂及其制备方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5213810A (en) * 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
ES2086022T3 (es) * 1991-07-23 1996-06-16 American Cyanamid Co Composiciones estables para administracion parenteral y su uso.
US5250236A (en) * 1991-08-05 1993-10-05 Gasco Maria R Method for producing solid lipid microspheres having a narrow size distribution
WO1994008610A1 (en) * 1992-10-16 1994-04-28 Smithkline Beecham Corporation Pharmaceutical emulsion compositions
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
JP3454385B2 (ja) * 1993-10-15 2003-10-06 啓次郎 佐藤 Ｏ／ｗ型皮膚用クリームの製造方法
US6333021B1 (en) * 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
JPH09151112A (ja) * 1995-11-30 1997-06-10 Noevir Co Ltd 微細エマルション組成物
FR2775441B1 (fr) * 1998-02-27 2000-04-28 Serobiologiques Lab Sa Matrice pour la preparation de microparticules ou de nanoparticules, procede de fabrication de telles particules et particules obtenues

Also Published As

Publication number Publication date
EP1176949A2 (de) 2002-02-06
BR0010354A (pt) 2002-03-05
AU4917900A (en) 2000-11-21
WO2000067728A2 (de) 2000-11-16
WO2000067728A3 (de) 2001-08-09
JP2002544155A (ja) 2002-12-24
MXPA01011343A (es) 2002-06-04
EP1176949B1 (de) 2014-12-10
CA2369594A1 (en) 2000-11-16

Similar Documents

Publication Publication Date Title
TR200103188T2 (tr) Sıvı ve katı lipit karışımları temelli lipid parçacıklar.
Dietz et al. Uptake of extracellular vesicles into immune cells is enhanced by the protein corona
Kusukawa et al. Probing guest geometry and dynamics through host-guest interactions this work was supported by the CREST (core research for evolutional science and technology) project of Japan science and technology corporation
Dausend et al. Uptake mechanism of oppositely charged fluorescent nanoparticles in HeLa cells
Rothbard et al. Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells
ATE324588T1 (de) Verkapselung von fluoreszierenden partikeln
KR930016091A (ko) 거의 수불용성인 약제의 고체 분산액을 제조하는 방법
TR200100855T2 (tr) Akut bozuklukların tedavisi için farmasötik komposizyon
BR0014087A (pt) Composições com pérolas de caroteno - xantofila estáveis e métodos de uso
MY158857A (en) Immune modulators, preparations and compositions including immune modulators, tests for evaluating the activity of immune modulators and preparation and compositions including the same, and methods
NO990276D0 (no) Ultralydavbildning av lever
BR9910481A (pt) Composição farmacêutica para comprimido de liberação não-contìnua
AR005305A1 (es) Composicion de particulas que contiene particulas con un nucleo hidrofilico dentro de una cubierta y procedimiento para la obtencion de dichas particulas
DE69911734D1 (de) Stabilisierte ascorbinsäure, zusammensetzung, und verfahren zu ihrer verwendung
Chandrabhas et al. Nucleotide‐Selective Templated Self‐Assembly of Nanoreactors under Dissipative Conditions
TR200003721T2 (tr) Spreyler için farmasötik formülasyonlar
TR200001023T2 (tr) Alfa-aril-N-Alkilnitronlar ve onları içeren farmasötik kompozisyonlar.
Mondal et al. Dual self-sorting by cucurbit [8] uril to transform a mixed micelle to vesicle
WO1999007728A3 (fr) Peptides lineaires derives de peptides antibiotiques, leur preparation et leur utilisation pour vectoriser des substances actives
ATE286005T1 (de) Granuliertes hydrophobes zusatzmaterial für zementzusammensetzungen
Goloub et al. Association behavior of ampholytic diblock copolymers
TR200101417T2 (tr) Sefuroksim aksetil içeren kompozisyonlar.
Najer et al. Differences in Human plasma protein interactions between various polymersomes and stealth liposomes as observed by fluorescence correlation spectroscopy
Marín-García et al. Low-toxicity metallosomes for biomedical applications by self-assembly of organometallic metallosurfactants and phospholipids
Hauptmann et al. High affinity proline uptake in rat brain synaptosomes